Structural features of the botulinum neurotoxin molecule that govern binding and transcytosis across polarized human intestinal epithelial cells

被引:61
作者
Maksymowych, AB
Simpson, LL
机构
[1] Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Philadelphia, PA 19107 USA
[2] Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA
关键词
D O I
10.1124/jpet.104.066845
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Experiments were done to help localize the minimum essential domain within the botulinum toxin molecule that is necessary for binding and transport across human gut epithelial cells. The data demonstrated that the neurotoxin alone, in the absence of auxiliary proteins, undergoes transcytosis. The neurotoxin by itself was examined in the single chain (unnicked serotype B) and dichain ( nicked serotype B, nicked serotype A) forms, and all displayed the ability to bind and penetrate epithelial barriers. In addition, the single chain and dichain molecules were examined in the oxidized and reduced states, and again all forms were transported. To further define the minimum essential domain, experiments were done with two toxin fragments: 1) the heavy chain, which was derived from native toxin, and 2) the carboxy-terminal portion of the heavy chain, which was generated by recombinant techniques. Interestingly, both fragments were fully competent in crossing epithelial barriers. These data suggest that a polypeptide derived from the toxin could be used as a carrier domain to transport other molecules across epithelial cells. In related experiments, physiological (i.e., potassium depletion) and pharmacological (i.e., chlorpromazine) manipulations were used to implicate clathrin-coated pits/vesicles as the structures responsible for endocytosis of toxin.
引用
收藏
页码:633 / 641
页数:9
相关论文
共 41 条
[1]  
Coffield JA, 1997, J PHARMACOL EXP THER, V280, P1489
[2]  
COLEMAN IW, 1954, CAN J BIOCHEM PHYS, V32, P27
[3]   Behavior of botulinum toxin in alimentary tract of rats and guinea-pigs [J].
Dack, GM .
JOURNAL OF INFECTIOUS DISEASES, 1926, 38 :174-181
[4]  
DanielsHolgate PU, 1996, J NEUROSCI RES, V44, P263, DOI 10.1002/(SICI)1097-4547(19960501)44:3<263::AID-JNR7>3.0.CO
[5]  
2-E
[6]   PURIFICATION AND AMINO-ACID-COMPOSITION OF TYPE-A BOTULINUM NEUROTOXIN [J].
DASGUPTA, BR ;
SATHYAMOORTHY, V .
TOXICON, 1984, 22 (03) :415-+
[7]   Organization and phylogenetic interrelationships of genes encoding components of the botulinum toxin complex in proteolytic Clostridium botulinum types A, B, and F: Evidence of chimeric sequences in the gene encoding the nontoxic nonhemagglutinin component [J].
East, AK ;
Bhandari, M ;
Stacey, JM ;
Campbell, KD ;
Collins, MD .
INTERNATIONAL JOURNAL OF SYSTEMATIC BACTERIOLOGY, 1996, 46 (04) :1105-1112
[8]   Structure-based sequence alignment for the β-trefoil subdomain of the clostridial neurotoxin family provides residue level information about the putative ganglioside binding site [J].
Ginalski, K ;
Venclovas, C ;
Lesyng, B ;
Fidelis, K .
FEBS LETTERS, 2000, 482 (1-2) :119-124
[9]   RETRACTED: Cocrystal structure of synaptobrevin-II bound to botulinum neurotoxin type B at 2.0 Å resolution (Retracted article. See vol 16, pg 795, 2009) [J].
Hanson, MA ;
Stevens, RC .
NATURE STRUCTURAL BIOLOGY, 2000, 7 (08) :687-692
[10]   ON THE SIZE OF THE TOXIC PARTICLE PASSING THE INTESTINAL BARRIER IN BOTULISM [J].
HECKLY, RJ ;
HILDEBRAND, GJ ;
LAMANNA, C .
JOURNAL OF EXPERIMENTAL MEDICINE, 1960, 111 (06) :745-759